Palisade Bio (PALI) Other Non-Current Liabilities (2012 - 2026)
Palisade Bio (PALI) reported Other Non-Current Liabilities of $62000.0 for Q1 2026, up 3000.0% year-over-year from $2000.0 in Q1 2025, and little changed on a QoQ basis from $62000.0 in Q4 2025.
Palisade Bio (PALI) has 15 years of Other Non-Current Liabilities data on file, last reported at $62000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 3000.0% year-over-year to $62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62000.0 (up 3000.0% YoY) and the FY2025 annual result came in at $62000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $62000.0 in Q1 2026 per PALI's latest filing, from $62000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2022 and bottomed at $2000.0 in Q2 2023.
- The 5-year median for Other Non-Current Liabilities is $61000.0 (2023), against an average of $224400.0.
- The widest annual swing landed in 2023, when Other Non-Current Liabilities plunged 99.57%; it then surged 3000.0% in 2026.
- Tracing PALI's Other Non-Current Liabilities over 5 years: stood at $392000.0 in 2022, then sank by 84.44% to $61000.0 in 2023, then slipped by 26.23% to $45000.0 in 2024, then jumped by 37.78% to $62000.0 in 2025, then changed by 0.0% to $62000.0 in 2026.
- Per Business Quant, the three latest PALI Other Non-Current Liabilities figures stand at $62000.0 (Q1 2026), $62000.0 (Q4 2025), and $283000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 283,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Sep 30, 2023 | 212,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 18,000.00 |
| Sep 30, 2022 | 392,000.00 |
| Jun 30, 2022 | 469,000.00 |
| Mar 31, 2022 | 1.69 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 9.43 Mn |
| Jun 30, 2021 | 20.53 Mn |
| Mar 31, 2021 | 171,202.00 |
| Dec 31, 2020 | 1.83 Mn |
| Sep 30, 2020 | 44,954.00 |
| Jun 30, 2020 | 62,623.00 |
| Mar 31, 2020 | 59,971.00 |
| Dec 31, 2019 | 84,596.00 |
| Sep 30, 2019 | 166,938.00 |
| Jun 30, 2019 | 487,723.00 |
| Mar 31, 2019 | 923,849.00 |
| Dec 31, 2018 | 583,734.00 |
| Sep 30, 2018 | 2.05 Mn |
| Jun 30, 2018 | 2.28 Mn |
| Mar 31, 2018 | 1,172.00 |
| Dec 31, 2017 | 3.85 Mn |
| Sep 30, 2017 | 3,400.00 |
| Jun 30, 2017 | 3.27 Mn |
| Mar 31, 2017 | 3.88 Mn |
| Dec 31, 2016 | 3.92 Mn |
| Sep 30, 2016 | 4.36 Mn |
| Jun 30, 2016 | 21,825.00 |
| Mar 31, 2016 | 200,739.00 |
| Dec 31, 2015 | 174,144.00 |
| Sep 30, 2015 | 143,730.00 |
| Jun 30, 2015 | 110,848.00 |
| Mar 31, 2015 | 146,165.00 |
| Dec 31, 2014 | 59,574.00 |
| Sep 30, 2014 | 222,970.00 |
| Jun 30, 2014 | 192,707.00 |
| Mar 31, 2014 | 160,338.00 |
| Dec 31, 2013 | 124,995.00 |
| Sep 30, 2013 | 89,650.00 |
| Jun 30, 2013 | 55,590.00 |
| Mar 31, 2013 | 22,356.00 |
| Dec 31, 2012 | 21,143.00 |